Aurinia Pharmaceuticals (AUPH) Cash from Operations (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Cash from Operations data on file, last reported at 32560000.0 in Q1 2026.

• Quarterly Cash from Operations rose 2404.62% year-over-year to 32560000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 166918000.0 (up 159.65% YoY) and the FY2025 annual result came in at 135658000.0, up 205.62% from the prior year.
• Cash from Operations slipped to 32560000.0 in Q1 2026, from 45668000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 45668000.0 in Q4 2025 to a low of 46746000.0 in Q1 2022.
• A 5-year average of 5859764.71 and a median of 10450000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations climbed 12.69% — and 2026, when it soared 2404.62%.
• Tracing AUPH's Cash from Operations over 5 years: stood at 10450000.0 in 2022, then soared by 36.96% to 14312000.0 in 2023, then surged by 110.41% to 30114000.0 in 2024, then jumped by 51.65% to 45668000.0 in 2025, then decreased by 28.7% to 32560000.0 in 2026.
• The last three Cash from Operations figures came in at 32560000.0 (Q1 2026), 45668000.0 (Q4 2025), and 44449000.0 (Q3 2025), per Business Quant data.